NYXH Nyxoah

Nyxoah Announces Change to Board of Directors

Nyxoah Announces Change to Board of Directors

Nyxoah Announces Change to Board of Directors

Mont-Saint-Guibert, Belgium – October 24, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Raymond Cohen resigned as member of the board of directors of the Company effective October 18, 2022.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit .

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:

Nyxoah

Loic Moreau, Chief Financial Officer



0

Jeremy Feffer, VP IR and Corporate Communications



 

Attachment



EN
24/10/2022

Underlying

NYXHNyxoah

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE
Free
NYXH NYXOAH

Publication relative à des notifications de transparence

Publication relative à des notifications de transparence          INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 30 mai 2025, 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) annonce qu’elle a reçu une notification de transparence comme détaillée ci-dessous. Vestal Point Capital Le 27 mai 2025, Nyxoah a reçu une notification de transparence de Vestal Point Capital suite à une acquisition ou ce...

May 30, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Publication relating to transparency notifications

Publication relating to transparency notifications                  REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), May 30, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Vestal Point Capital On May 27, 2025, Nyxoah received a transparency notification from Vestal Point Capital following an acquisition or disposal of voting securities...

May 30, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Nyxoah to Present at the Jefferies Global Healthcare Conference

Nyxoah to Present at the Jefferies Global Healthcare Conference Nyxoah to Present at the Jefferies Global Healthcare Conference Mont-Saint-Guibert, Belgium – May 28, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies Global Healthcare Conference, which takes place June 3 – 5, 2025 in New York. Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a ...

May 28, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Nyxoah Participera à la Jefferies Global Healthcare Conference

Nyxoah Participera à la Jefferies Global Healthcare Conference Nyxoah Participera à la Jefferies Global Healthcare Conference Mont-Saint-Guibert, Belgique – 28 mai 2025, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») une société de technologie médicale développant des alternatives thérapeutiques innovantes pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui qu’elle participera à la Jefferies Global Healthcare Conference, qui aura lieu du 3 au 5 juin 2025 à New York. Olivier Taelman, Chief Executive Off...

May 28, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Information on the total number of voting rights and shares

Information on the total number of voting rights and shares Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), May 23, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,430,026.16 Total number of securities carrying voting rights: 37,429,265 (all ordinary shares) Total number of voting rights (= denominator): 37,429,265 (all relating ...

May 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch